Health Catalyst files resale of 25,795 restricted shares
Health Catalyst, Inc. (restricted shares reported for sale) The filing reports a proposed resale of 25,795 restricted shares to be sold through Morgan Stanley Smith Barney LLC on 03/02/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Health Catalyst, Inc. (restricted shares reported for sale)
The filing reports a proposed resale of 25,795 restricted shares to be sold through Morgan Stanley Smith Barney LLC on 03/02/2026. The filing also documents prior restricted-share dispositions by Daniel Burton: 55,715 shares on 12/01/2025 and 28,875 shares on 02/26/2026. Shares outstanding were 70,730,884 as of 03/02/2026.
Insights
Form 144 shows a planned resale of restricted stock and recent insider dispositions.
The filing lists a proposed sale of 25,795 restricted shares through Morgan Stanley Smith Barney LLC on 03/02/2026. It also records prior restricted-stock sales by Daniel Burton: 55,715 shares on 12/01/2025 for $161,584.64 and 28,875 shares on 02/26/2026 for $50,467.73.
Cash treatment and exact purchasers are not stated; timing and execution depend on broker handling and applicable resale conditions. Subsequent filings or transaction confirmations may report completion details and final proceeds.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who reported recent restricted-stock sales in the HCAT filing?
Which broker is handling the proposed HCAT resale?
Are proceeds or purchasers identified in the HCAT Form 144?
AI-generated analysis. How Rhea-AI works. Not financial advice.